A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
PreTerm Labor (prior to 37 weeks gestation) is the largest single cause of infant morbidity and mortality and is frequently associated with long-term disability. Oxytocin is a hormone produced by the body during labor. GSK221149 is an experimental drug that will be used to block the effects of oxytocin, and therefore pause or prevent contractions. In this study, the pharmacokinetics of various modified release formulations of GSK221149 will be investigated in healthy non-pregnant adult subjects.
Blood samples will be drawn and analyzed to assess how the body handles the drug over a 24 hour period during each study session. [ Time Frame: over a 24 hour period during each study session. ]
Secondary Outcome Measures :
Safety and tolerability will be assessed by blood pressure, ECGs, and blood sampling over a 24 hour time period during each study session.. [ Time Frame: over a 24 hour period during each study session. ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy males and non-pregnant female
Between the ages of 18 and 50 years old.
Females may be of child-bearing or non-child-bearing potential.
BMI of between 19 and 30 kg/m2 (weight of greater than 110lbs).
History of smoking within past 6 months
Regular alcohol consumption averaging 7 drinks or more per week
Subject is positive for hepatitis C antibody, hepatitis B surface antigen, or HIV
Use of prescription or non-prescription drugs within 14 days of study start